Transplant Immunosuppression: Balance Rejection and Toxicity

Clinical Mastery · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Graft function, proteinuria, infection surveillance, preventive care, cardiovascular risk, and quality of life remain important after the early transplant period.

Complementary immune targets require balanced monitoring. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Complementary immune targets require balanced monitoring. T-cell activation — Calcineurin pathway targets; Cell proliferation — Antimetabolite and related targets; Graft protection — Reduce rejection risk; Safety and adherence — Infection, toxicity, trough timing and interactions. Graft dysfunction is not always rejection. Coordinate changes with the transplant team. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Complementary immune targets

Induction and maintenance regimens suppress different parts of the immune response. The combination reflects rejection risk, organ function, and treatment history.

Do not label all graft dysfunction rejection

Check volume, infection, obstruction, vascular problems, drug exposure, adherence, and recurrent disease. Review urine findings and ultrasound when indicated. A creatinine rise may need biopsy, but increasing immunosuppression before considering infection or obstruction can worsen the wrong problem.

A trough needs timing and interaction history

For tacrolimus monitoring, verify that blood was drawn at the intended predose trough and record the last dose, formulation, diarrhea, and interacting medicines. A mistimed level should not trigger an automatic dose change. Use the transplant program’s target for the posttransplant phase and immunologic risk.

Coordinate adjustments

Changes should be made through the transplant team with attention to rejection risk, infection, malignancy, metabolic effects, and pregnancy considerations.

Solve adherence barriers

Cost, complexity, side effects, cognition, and beliefs require practical support. Missed doses are a clinical problem to understand, not simply a label.

Follow the whole recipient

Graft function, proteinuria, infection surveillance, preventive care, cardiovascular risk, and quality of life remain important after the early transplant period.

Continue learning